US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
Bill 119HR9774IH proposes expedited FDA approval for priority nonprescription drugs, potentially reducing time-to-market for certain OTC switches. This could affect drug manufacturers' regulatory strategies and supply chain planning.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; bill is in early legislative stage.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Introduction of a bill to amend the FD&C Act to create an expedited approval pathway for priority nonprescription drugs.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Monitor bill progress; assess potential impact on OTC switch strategies and resource allocation.
Deadline
No immediate deadline; bill is in early legislative stage.
Source: https://www.govinfo.gov/app/details/BILLS-119hr9774ih
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026
- US-CONGRESS BILLS-119s4994is: Our Nation’s Supply chain for Healthcare has Over Reliance Elsewhere Act; ONSHORE Manufacturing Act
- US-CONGRESS BILLS-119s4987is: Pharmaceutical Investment Oversight and Accountability Act
- FDA Presses Forward on Patient-Focused Drug Development, Releases Final Guidance Focused on Fit-For-Purpose Clinical Outcome Assessments - akingump.com
- CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRA - fda.gov